6 Best Peptides for H. pylori

What to Know Before Choosing a Peptide for H. pylori

H. pylori infects roughly 44 percent of the global population and is the leading cause of peptic ulcer disease, chronic gastritis, and a significant driver of gastric cancer risk. The standard treatment as of 2026 is antibiotic-based combination therapy, and those regimens work well when they work. The problem is antibiotic resistance. Clarithromycin and metronidazole resistance rates are high enough in many regions that first-line regimens fail in a meaningful proportion of patients, and that gap is exactly what has pushed researchers and people who research their own conditions toward alternatives, including peptides.

Here is what every reader needs to understand before going further: there are no FDA-approved peptide therapies for H. pylori. There are no completed human clinical trials testing antimicrobial peptides against this infection. Every compound in this guide sits somewhere between interesting preclinical data and community-reported experiential use, and that evidence state is described honestly in each entry. A peptide earned a slot here because people use it or are actively discussing it for H. pylori, not because it has cleared a regulatory bar or finished a phase-three trial. Evidence strength is stated plainly inside each entry rather than used as a filter for inclusion.

The entries that follow are numbered by how prominently each compound appears in research and real-world discussion for this goal. That order reflects depth of use and discussion, not a verdict on which compound is better or a recommendation that any particular reader should choose one over another. The right approach to H. pylori starts with a conversation with a qualified healthcare provider about approved antibiotic therapy. Peptides in this context are a parallel conversation happening in research labs and online communities, and this guide maps that conversation honestly.

1. LL-37: The Antimicrobial Peptide H. pylori Suppresses

LL-37 is the only human cathelicidin, which means it is the sole member of that host-defense peptide family that the body naturally produces. Neutrophils, macrophages, and epithelial cells all synthesize it as part of the innate immune system's first response to bacterial invasion. What makes LL-37 particularly relevant to H. pylori is not just that cathelicidins as a class have documented antibacterial activity, but that H. pylori has evolved a specific strategy to neutralize it. The bacterium actively downregulates cathelicidin expression in the gastric mucosa, suppressing the very defense mechanism that would otherwise attack it. That immune evasion strategy is well-described in the published research and gives LL-37 a mechanistic narrative that no other compound in this list can match.

How LL-37 works against bacteria is well understood at the molecular level. It is a cationic, alpha-helical peptide, meaning it carries a positive charge and folds into a helical shape that allows it to interact electrostatically with the negatively charged surface of bacterial cell membranes. Once it inserts into the membrane, it disrupts the lipid bilayer directly, leading to permeabilization and bacterial death. That mechanism is entirely distinct from how antibiotics work, which is part of what makes antimicrobial peptides like LL-37 theoretically interesting when antibiotic-resistant H. pylori strains are the clinical problem. Beyond its direct antibacterial action, LL-37 also modulates toll-like receptor signaling and promotes epithelial repair, both of which are relevant to a chronic infection that progressively degrades the gastric lining.

The evidence picture for LL-37 in H. pylori is preclinical. Cathelicidins as a class are identified in the published review literature as one of the primary groups of host-derived antimicrobial peptides with anti-H. pylori relevance. The specific mechanism by which H. pylori downregulates LL-37 has been studied and is considered a genuine virulence and immune evasion factor. What has not been established, as of 2026, is any human clinical trial evaluating exogenous LL-37 administration for H. pylori infection, and no community reports of people self-administering LL-37 specifically for this infection were found in the sources reviewed. LL-37 ranks first here because its mechanistic relevance to this infection is the most scientifically grounded of any compound on the list. The clinical use case has not been built yet, but the biological rationale for why restoring LL-37 activity could theoretically help the host fight this particular bacterium is more direct and better supported than any other peptide in this field.

2. BPC-157: For Gastric Mucosal Healing After Infection

BPC-157 is a 15-amino acid synthetic peptide derived from a protective protein found in human gastric juice. That origin is relevant here. It was identified from the stomach's own protective secretions, and the bulk of what has been studied in animal models centers on its effects on the gastric mucosa: promoting tissue healing, reducing inflammation, and restoring the structural integrity of the lining that H. pylori persistently disrupts. It is worth stating clearly at the outset what BPC-157 is not in this context: it has no published direct antimicrobial activity against H. pylori. It does not kill the bacterium. Its relevance is as a mucosal healing and anti-inflammatory compound used during recovery from infection or alongside eradication therapy, not as a replacement for it.

The mechanism through which BPC-157 supports gastric recovery is reasonably well studied in animal models. It promotes upregulation of epidermal growth factor, a signaling protein that triggers tissue repair. It reduces pro-inflammatory cytokine production and appears to modulate NF-kB signaling, the same inflammatory pathway that H. pylori activates through its CagA virulence factor and Type IV Secretion System. It has angiogenic properties, meaning it supports the formation of new blood vessels to deliver the raw materials for tissue repair. And it appears to strengthen the epithelial tight junctions that H. pylori's CagA toxin works to disrupt. Each of those actions is mechanistically relevant to what this infection does to the gastric lining, even if BPC-157 is not addressing the bacterium itself.

No published human clinical trial has evaluated BPC-157 for H. pylori treatment or post-eradication mucosal recovery as of 2026. The preclinical animal data supporting gastroprotective effects is substantive, but it has not been translated into a human study for this specific indication. The most detailed account of BPC-157 use for H. pylori that surfaced in the sources reviewed is a single post from the r/HPylori community, where one user reported taking BPC-157 orally, starting at a lower dose and escalating over time, and experiencing remarkable symptom improvement within about one week and what they described as a complete restoration of normal gastric function within two to three weeks. The user also stated that a subsequent upper endoscopy showed no signs of inflammation, ulcers, or active H. pylori. That is a striking account, but it is a single anecdotal report, not a controlled study, and it is not clear whether the user was simultaneously undergoing antibiotic eradication therapy. It cannot be read as evidence that BPC-157 eradicates H. pylori. It is the strongest signal in the community literature and is why BPC-157 generates more discussion in the H. pylori self-research community than any other peptide in this guide. BPC-157 is sold as a research chemical and is not FDA-approved for any indication.

3. KPV: For the Inflammatory Cascade H. pylori Triggers

KPV is a tripeptide composed of three amino acids: lysine, proline, and valine. It is derived from the C-terminus of alpha-MSH, a signaling molecule involved in immune regulation and inflammation control. KPV has been studied primarily in the context of inflammatory bowel disease and gut mucosal inflammation, where its ability to suppress specific inflammatory pathways has been the focus. Its relevance to H. pylori comes not from any antimicrobial property but from how precisely its mechanism aligns with the inflammatory damage H. pylori causes in the stomach.

When H. pylori infects the gastric mucosa, one of the central events is the activation of NF-kB signaling in epithelial cells, which drives production of interleukin-8, a cytokine that recruits neutrophils and sustains the chronic inflammatory state of H. pylori-associated gastritis. KPV inhibits NF-kB signaling and reduces IL-8 production. It does this through melanocortin receptors, specifically MC1R and MC3R, which are expressed on both immune cells and epithelial cells. Food-derived bioactive peptides that reduce IL-8 and exert anti-adhesive effects against H. pylori have been studied for exactly this pathway, and KPV operates through the same anti-inflammatory axis. The mechanistic alignment is real and specific, even though KPV has never been tested against H. pylori directly in any published study.

The evidence for KPV in H. pylori is the thinnest of the three community-discussed compounds in this list. No published human clinical trial exists for KPV in any H. pylori-related indication as of 2026. No community reports of KPV being used specifically for H. pylori were found in the sources reviewed. What exists is a mechanistically plausible case grounded in KPV's well-characterized anti-inflammatory action, its established relevance to gut mucosal pathology, and the specific overlap between its targets and H. pylori's primary inflammatory signaling route. KPV is sold as a research chemical and is not FDA-approved for any indication. Its potential role in this space, if it has one, is as an adjunct to eradication therapy aimed at reducing the inflammatory burden during or after treatment, not as a standalone approach to the infection itself.

4. TP4: The Most Studied Antimicrobial Candidate in Animal Models

TP4, also called tilapia piscidin 4, is a cationic antimicrobial peptide isolated from Nile tilapia. It is alpha-helical in structure and carries a high positive charge, the same basic architecture that lets LL-37 disrupt bacterial cell membranes. TP4 has been tested more directly against H. pylori in animal research than any other antimicrobial peptide compound reviewed for this guide, and it has shown activity against multidrug-resistant strains, which is the clinical problem that gives the antibiotic-resistance angle its urgency.

In a mouse model study, TP4 significantly reduced H. pylori bacterial load. It was effective against strains that had developed resistance to standard antibiotics. Toxicity testing in mice and rabbits across oral, dermal, and both acute and sub-acute administration found no adverse effects, which is an encouraging early safety signal for a compound being considered as a potential oral therapeutic. That combination of meaningful antibacterial activity against resistant strains and a clean animal toxicity profile is what places TP4 among the more developed research candidates for this infection.

The evidence remains strictly preclinical. No human clinical trial has been conducted for TP4 in H. pylori treatment as of 2026. TP4 does not appear in community discussions around H. pylori self-treatment; it lives entirely in the academic literature. It is included here because people following the research on peptide options for H. pylori increasingly encounter TP4 in that literature, and it represents the kind of antimicrobial peptide the LL-37 section describes in principle: a cationic, alpha-helical AMP that can directly kill H. pylori, including drug-resistant strains, in a controlled animal model. The translation to human use has not occurred, and the delivery challenges that affect all oral antimicrobial peptides, primarily rapid degradation by gastric proteases and the low-pH environment of the stomach, remain unsolved for TP4.

5. PL2: The pH-Sensitive Antimicrobial Built for the Stomach

PL2 is a pH-sensitive synthetic polypeptide designed around a specific insight about the H. pylori treatment problem: the stomach's low pH destroys most therapeutic peptides before they can reach the bacteria, but that same acidic environment could be turned into an activation condition if the peptide is engineered to become active at low pH rather than degrade in it. PL2 was specifically designed to be antimicrobially active in the acidic gastric environment, which is where H. pylori lives and where most antimicrobial peptide approaches fall apart.

In preclinical studies, PL2 killed more than 90 percent of H. pylori at pH 3.0, the approximate acidity of the stomach. It demonstrated activity against drug-resistant strains, which addresses the same resistance gap that motivates interest in non-antibiotic approaches. The pH-sensitive design is what mechanistically distinguishes PL2 from most other antimicrobial peptides studied against H. pylori. The majority of AMPs in this field are tested under neutral or near-neutral conditions that do not reflect the gastric environment. PL2 was engineered around that constraint from the ground up.

The research on PL2 is strictly preclinical, conducted in cell-based and early laboratory models. No animal efficacy study and no human clinical trial has been completed or published as of 2026. PL2 does not appear in community self-treatment discussions. It is included here because people who follow the antimicrobial peptide literature on H. pylori encounter it as one of the more rationally designed candidates in the field, and the problem it is built to solve, stability and activation in the stomach's acid environment, is the central delivery challenge for the entire class of antimicrobial peptides being explored for this infection.

6. C12G2: The Hydrogel Delivery Approach to the Gastric Mucosa

C12G2 is a self-assembling antimicrobial peptide that, when formulated as a hydrogel rather than administered in solution, has shown H. pylori-eradicating activity in mouse models. The delivery format is what makes C12G2 notable. The core problem for antimicrobial peptides against H. pylori is that peptides administered orally are typically broken down by proteases and stomach acid before they can reach the bacteria colonizing the gastric mucosa. Formulating C12G2 as a hydrogel slows that degradation, prolongs contact time with the mucosal surface, and was associated with reduced cytotoxicity compared to the same compound in solution form, meaning it was less damaging to the host tissue it needed to penetrate.

In mouse model research, C12G2 in hydrogel form eradicated H. pylori within minutes of contact and resolved associated inflammation. Those are notable results for a preclinical study. The cytotoxicity reduction compared to solution administration is also a meaningful finding, because cytotoxicity against host mucosal cells is one of the real concerns when using highly active antimicrobial compounds in the stomach environment. The hydrogel delivery mechanism represents one of the more technically developed solutions to the core challenge of getting an antimicrobial peptide to stay in contact with H. pylori long enough to work.

C12G2 in hydrogel form is a research-stage compound. No human clinical trial has been conducted. It does not appear in community use discussions. Like PL2, it earns its place here because it represents a serious research direction that people following the peptide literature on H. pylori encounter, and because the hydrogel delivery mechanism is the same class of solution being explored across multiple research groups working on the peptide-based H. pylori problem.

How These Peptides Compare

Frequently Asked Questions

Can peptides replace antibiotic therapy for H. pylori?

No peptide has been shown in human studies to eradicate H. pylori, and none is approved for that purpose. The current standard of care is antibiotic-based combination therapy, which achieves eradication in the majority of patients when the regimen is matched to local resistance patterns. Peptides in this space are either being studied as potential future options or are being used experientially by people seeking adjunctive support, not as replacements for antibiotic treatment.

Are any of these peptides available with a prescription?

None of the peptides covered in this guide are available by prescription for H. pylori treatment. The FDA-approved treatment for H. pylori that involves a novel mechanism is Talicia, a three-drug combination of omeprazole, amoxicillin, and rifabutin available via prescription including through telemedicine. Compounds like BPC-157 and KPV are sold as research chemicals and are not legally approved for human use in the United States.

Why does H. pylori make the peptide approach scientifically interesting?

H. pylori has developed a range of strategies to survive the stomach and evade the immune response, including actively downregulating the host's own antimicrobial peptide production. That immune evasion piece is what gives compounds like LL-37 their scientific rationale: the bacterium suppresses the very defense mechanism that would otherwise attack it. Additionally, growing antibiotic resistance means researchers are actively looking for mechanisms that work differently from conventional antibiotics, and the membrane-disruption mechanism of most antimicrobial peptides fits that description.

What is the difference between a peptide that kills H. pylori and one that heals the damage it causes?

Antimicrobial peptides like LL-37, TP4, PL2, and C12G2 are studied for their ability to directly kill or inhibit H. pylori as a bacterium. BPC-157 and KPV work differently: they address the damage H. pylori does to the gastric lining and the inflammatory response it triggers, rather than targeting the bacterium itself. A compound that heals mucosal damage is not an eradication therapy, and it may help with symptoms and recovery without clearing the infection.

Is there human evidence for any of these peptides in H. pylori?

As of 2026, no published human clinical trial has evaluated any antimicrobial peptide as a treatment for H. pylori infection. The evidence base across all six compounds in this guide is either preclinical, meaning animal models and cell-based laboratory studies, or experiential, meaning user-reported accounts from the H. pylori self-research community. That is an honest description of where the field stands, and it is the reason these compounds are discussed as research-stage candidates rather than treatment options.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for H. pylori in one place.